Calendar · pharmadog

Week of Apr 20, 2026

Apr 24, 2026phase 3 completion78d agoChong Kun Dang Pharmaceutical Corp. — CKD-398 (Phase III Trial Completion)CKD-398

Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

Apr 24, 2026phase 3 completion78d agoImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd — timdarpacept (Phase III Trial Completion)timdarpacept

Therapy area: Oncology. Indication: Chronic Myelomonocytic Leukemia (CMML)

full page →timdarpacept →source: globaldata

Apr 24, 2026phase 3 completion78d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →minoxidil →source: globaldata

Apr 24, 2026phase 3 completion78d agoShriners Hospitals for Children — bupivacaine ER (Phase III Trial Completion)bupivacaine

Therapy area: Central Nervous System, Mouth and Dental Disorders. Indication: Post-Operative Pain, Unspecified Mouth and Dental Disorders

full page →bupivacaine →source: globaldata

Apr 25, 2026phase 3 completion77d agoMashhad University of Medical Sciences — acetazolamide (Phase III Trial Completion)ACETAZOLAMIDE

Therapy area: Central Nervous System. Indication: Epilepsy

full page →ACETAZOLAMIDE →source: globaldata

Apr 25, 2026phase 3 completion77d agoAin Shams University — lidocaine (Phase III Trial Completion)LIDOCAINE

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →LIDOCAINE →source: globaldata

Apr 26, 2026phase 3 completion76d agoBharatiya Sanskriti Darshan Trust — ayurvedic medicine (Phase III Trial Completion)ayurvedic medicine

Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

full page →ayurvedic medicine →source: globaldata

Apr 26, 2026phase 3 completion76d agoHomi Bhabha Cancer Hospital Research Centre — megestrol (Phase III Trial Completion)megestrol

Therapy area: Central Nervous System, Gastrointestinal, Genito Urinary System, Respiratory. Indication: Anorexia Nervosa, Unspecified Gastrointestinal Disorders, Unspecified Genito Urinary Disorders, Unspecified Respiratory Disorders

full page →megestrol →source: globaldata

Apr 26, 2026phase 3 completion76d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

Therapy area: Infectious Disease. Indication: Rabies

full page →rabies vaccine →source: globaldata

Apr 26, 2026phase 3 completion76d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

full page →diltiazem →source: globaldata

Week of Apr 27, 2026

Apr 27, 2026phase 3 completion75d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →elranatamab →source: globaldata

Apr 27, 2026phase 3 completion

Week of Jul 6, 2026

07/08/2026adcom3d agoAdvisory Committee Calendar

This page contains notices of advisory committee meetings. Refer to the individual meeting link below for more information on the anticipated format of each meeting. For previous years' advisory committee calendars, see the FDA Archive.

full page →fda adcom ↗